title: [Оptimization of stable angina standard therapy in patients with concomitant osteoarthritis and obesity].
abstract: The aim of the study was to optimize standard therapy in patients with stable angina pectoris (SAP) associated with osteoarthritis (OA) and obesity through a combined, concomitant therapy of OA and obesity. To address this goal, on a background of standard therapy of stable angina was carried concomitant therapy of osteoarthritis and obesity, which included non-steroidal anti-inflammatory drugs, a selective COX-2 inhibitors, chondro-protective agents, anti-diabetic drug from the group of biguanides (metformin), a drug that affects the centers of hunger and reduces appetite in obese patients "Tsefamadar" (active ingredient Trituration Madara D4 - 250 mg), as well as diet with reduced energetic properties, number 8, and its modification: 8a (for obese patients with I-II degree), 80 (for obese patients III degree). As a result of the proposed method of treatment had improved the clinical course of CCH due to lower body weight, body mass index (BMI) and abdominal obesity indexes (AOI), which were characterized by decreasing the duration and frequency of angina attacks, reducing the number of nitroglycerin tablets taken, and also increased exercise tolerance (ET). Correction of carbohydrate metabolism on the background of metformin treatment, helped to improve lipid metabolism, suggesting greater efficiency of HMG-CoA reductase inhibitors (statins) in patients with SAP on a background of the proposed method. The decrease in CRP levels in patients with SAP, combined with OA and obesity with concomitant therapy by the proposed method, indicates a decrease in systemic inflammation.
authors: Iu V
authors: IuV
authors: Teslenko
mesh_terms: D000328:Adult; D000368:Aged; D060050:Angina, Stable / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage; D015992:Body Mass Index; D001835:Body Weight; D050260:Carbohydrate Metabolism / Q000187:drug effects; D051546:Cyclooxygenase 2 / Q000378:metabolism; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage; D017079:Exercise Tolerance / Q000187:drug effects; D005260:Female; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D008687:Metformin / Q000008:administration & dosage; D008875:Middle Aged; D005996:Nitroglycerin / Q000008:administration & dosage; D009765:Obesity / Q000150:complications / Q000188:drug therapy* / Q000473:pathology*; D010003:Osteoarthritis / Q000150:complications / Q000473:pathology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D008687:Metformin; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D005996:Nitroglycerin